Discover · sciam.com

GLP-1 drugs are entering a new chapter

60-Second Science sciam.com

This is what was read here when it was published. Scientific American no longer carries it in what it publishes now.

In this episode of Science Quickly, Scientific American’s associate health editor Lauren Young joins host Kendra Pierre-Louis to talk about how the story of GLP‑1 drugs such as Ozempic, Wegovy and Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes treatments, their rise as blockbuster weight‑loss medications and the ensuing complications—including the expanding market for compounded drugs. And we look at how the landscape has only grown more complex as researchers explore surprising potential uses for GLP‑1s, from addiction treatment to cardiovascular benefits, even as new concerns emerge about long‑term effects.

Compound weight-loss drugs are everywhere. The FDA is cracking down

More ways to use this
Open on another device
Scan this QR code to open the same public page

Scan to open this page. Your saved notes and account access are not included.

Download QR code

Open the page link

Named in it

Keep going

Each of these is read from what this estate already kept: the feed a piece came through, the publisher behind it, the credits and topics the publisher printed. None of it is a recommendation, an identity or a record kept anywhere else.

Also from 60-Second Science

  1. The sopranos of the jungleScientific American sciam.com
  2. We started a book club. Naturally, we picked a book on fungiScientific American sciam.com
  3. Cover Story: The End of Math as We Know ItScientific American sciam.com
  4. A Roman-era frog whodunit and more science surprisesScientific American sciam.com
  5. Did I stutter?Scientific American sciam.com
  6. Could this be the strongest El Niño in 1,000 years?Scientific American sciam.com